Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions

Reuters

05-20

Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions

Stryker Corporation has announced that its OptaBlate® Basivertebral Nerve Ablation System (OptaBlate BVN) has received 510(k) clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, Florida.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL90381) on May 19, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536390486"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536390486\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536390486?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 01:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536390486","market":"nz","top_or_hot":-1,"title":"Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stryker Corporation has announced that its OptaBlate® Basivertebral Nerve Ablation System (OptaBlate BVN) has received 510(k) clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain &amp; Neuroscience Annual Meeting in Miami, Florida.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL90381) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 01:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stryker Corporation has announced that its OptaBlate® Basivertebral Nerve Ablation System (OptaBlate BVN) has received 510(k) clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain &amp; Neuroscience Annual Meeting in Miami, Florida.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL90381) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL45G7dC:1","article_id":"2536390486","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536390486","pubTimestamp":1747674076,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stryker Corporation Receives FDA Clearance for OptaBlate BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions. Stryker Corporation has announced that its OptaBlate Basivertebral Nerve Ablation System  has received 510 clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"史赛克公司OptaBlate®BVN基础脊神经消融系统获FDA批准，拓展先进疼痛治疗解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":0.9},"content_text":"Stryker Corporation Receives FDA Clearance for OptaBlate® BVN Basivertebral Nerve Ablation System, Expanding Advanced Pain Therapy Solutions\n    \n\n        Stryker Corporation has announced that its OptaBlate® Basivertebral Nerve Ablation System (OptaBlate BVN) has received 510(k) clearance from the U.S. Food and Drug Administration. This clearance marks a significant advancement in Stryker's medical technology portfolio, as OptaBlate BVN is designed to provide relief from chronic vertebrogenic low back pain through a minimally invasive procedure. The system targets the basivertebral nerve using radiofrequency ablation technology, offering long-lasting pain relief for patients. The introduction of OptaBlate BVN is set to be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, Florida.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL90381) on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}